Marwah Vikas, Choudhary Robin, Adhikari Sudipt, Pemmaraju Arpita, Menon A S, Manrai Manish, Ajai Kumar Tentu, Verma Shipra
Professor & Head (Pulmonary, Critical Care & Sleep Medicine), Army Institute of Cardiothoracic Sciences (AICTS), Pune, India.
Assistant Professor (Pulmonary Medicine, Critical Care & Sleep Medicine), Base Hospital, Delhi Cantt, India.
Med J Armed Forces India. 2023 May 18;80(Suppl 1):S180-4. doi: 10.1016/j.mjafi.2023.03.006.
Neutralizing antibodies cocktail (casirivimab and imdevimab) has received emergency use authorization recommendation by Food and Drug Administration (FDA) and WHO for mild-to-moderate COVID-19 infection in specific high-risk groups. Antibodies cocktail has shown promising results in preventing progression to severe disease, but the real-world experience is still evolving. Herein, we present a retrospective analysis of 22 patients who were administered the antibodies cocktail between August 2021 and March 2022 at our tertiary care center.
We conducted an observational retrospective analysis of clinicoradiological, inflammatory parameters, progression of the disease, and outcome among 22 mild and moderate COVID-19 patients treated with antibodies cocktail.
The mean age was 67.7 years (SD ± 18.3) and comprised of 13 males (59%), while 9 were females (40.9%). Nine (40.9%) patients were fully vaccinated with two doses, nine (40.9%) were partially vaccinated with one dose while four patients (18.2%) were unvaccinated, and the rest were unvaccinated. Diabetes and hypertension were the commonest comorbidities; hematological and solid organ malignancies were other comorbidities. Eight patients had radiological opacities consistent with COVID-19 pneumonia and had shown significant regression in four patients after the therapy. None of our patients required supplemental oxygen or progressed to severe acute respiratory distress syndrome. All patients were discharged in a stable condition within 6 days of the therapy.
The neutralizing antibodies cocktail has shown encouraging results in our analysis in preventing progression to severe disease in patients with high-risk conditions.
中和抗体鸡尾酒疗法（卡西瑞单抗和依德维单抗）已获得美国食品药品监督管理局（FDA）和世界卫生组织（WHO）的紧急使用授权推荐，用于特定高危人群的轻至中度新型冠状病毒肺炎（COVID-19）感染。抗体鸡尾酒疗法在预防疾病进展为重症方面已显示出有前景的结果，但实际应用经验仍在不断发展。在此，我们对2021年8月至2022年3月期间在我们的三级医疗中心接受抗体鸡尾酒疗法的22例患者进行了回顾性分析。
我们对22例接受抗体鸡尾酒疗法治疗的轻至中度COVID-19患者的临床放射学、炎症参数、疾病进展和结局进行了观察性回顾分析。
患者的平均年龄为67.7岁（标准差±18.3），其中男性13例（59%），女性9例（40.9%）。9例（40.9%）患者完成了两剂全程疫苗接种，9例（40.9%）患者接种了一剂部分疫苗，4例患者（18.2%）未接种疫苗，其余为未接种疫苗者。糖尿病和高血压是最常见的合并症；血液系统和实体器官恶性肿瘤是其他合并症。8例患者有与COVID-19肺炎相符的放射学混浊，其中4例患者在治疗后混浊明显消退。我们的患者均未需要补充氧气或进展为重症急性呼吸窘迫综合征。所有患者在治疗后6天内均病情稳定出院。
在我们的分析中，中和抗体鸡尾酒疗法在预防高危患者疾病进展为重症方面显示出令人鼓舞的结果。
